<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970450</url>
  </required_header>
  <id_info>
    <org_study_id>DAAnaBaselParacetamol 2</org_study_id>
    <nct_id>NCT00970450</nct_id>
  </id_info>
  <brief_title>The Central Analgesic Effects of Paracetamol on Serotonergic Pathways</brief_title>
  <official_title>The Central Analgesic Effects of Paracetamol on Serotonergic Pathways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Introduction&#xD;
&#xD;
           Paracetamol, an analgesic prescribed daily, has been in use for more than 50 years.&#xD;
           Surprisingly, its mode of action is still unclear. One postulated mechanism is the&#xD;
           reinforcement of descending inhibitory pathways. A recent publication in a human pain&#xD;
           model raises the question of whether or not Paracetamol acts according to a central&#xD;
           serotonergic mechanism. Unfortunately, the chosen model was unable to differentiate&#xD;
           between overall pain, secondary hyperalgesia and allodynia. In particular, secondary&#xD;
           hyperalgesia and allodynia are central effects.&#xD;
&#xD;
           The planned study will examine the central analgesic effects of paracetamol on allodynia&#xD;
           and hyperalgesia by blocking the central effect by adding tropisetron. It will be based&#xD;
           on an internationally accepted model for the initiation of secondary hyperalgesia, which&#xD;
           was developed and tested by colleagues in Erlangen.&#xD;
&#xD;
        2. Study work plan&#xD;
&#xD;
           This prospective, randomized, placebo-controlled, double-blinded, cross-over trial in 16&#xD;
           male volunteers will address pain ratings and the area of secondary&#xD;
           hyperalgesia/allodynia in a human model of electrically evoked pain and compare four&#xD;
           different treatment scenarios:&#xD;
&#xD;
             -  Paracetamol 1 g;&#xD;
&#xD;
             -  Paracetamol, 1 g and Tropisetron 5 mg;&#xD;
&#xD;
             -  Tropisetron, 5 mg; and&#xD;
&#xD;
             -  Saline.&#xD;
&#xD;
           Each volunteer will be allocated to each scenario in a cross-over fashion. Four separate&#xD;
           treatment trials, at least two weeks apart, will be performed. Each volunteer will be&#xD;
           familiarized with the stimulation procedure prior to participation.&#xD;
&#xD;
        3. Ethical considerations&#xD;
&#xD;
           Informed consent will be obtained from each volunteer. In addition, each volunteer will&#xD;
           receive remuneration after participating in the study.&#xD;
&#xD;
           Paracetamol is considered to be a very safe drug in healthy patients. Tropisetron,&#xD;
           another safe medication, is routinely used in anaesthetic practice as an antiemetic&#xD;
           drug. Headache, flush and liver parameter elevation are very rare side effects of minor&#xD;
           importance in our daily clinical work as anaesthetists.&#xD;
&#xD;
           This pain provoking procedure was developed at the University Erlangen Germany. It is a&#xD;
           standardized method and has repeatedly received approval by research ethics committees&#xD;
           internationally. Furthermore, the investigators applied this model to a recent study in&#xD;
           Basel (cf your decision &quot;study protocol 330/07;&quot; unpublished data, analysis and writing&#xD;
           in progress).&#xD;
&#xD;
        4. Patient number and timetable&#xD;
&#xD;
           The investigators will examine 16 volunteers and expect the experimental component to&#xD;
           last 3 months. The investigators plan to complete this study within one year.&#xD;
&#xD;
        5. Study importance&#xD;
&#xD;
      The mode of action of paracetamol remains unclear. The investigators think that this study&#xD;
      will enable them to answer important questions concerning the action of paracetamol. The&#xD;
      investigators hope that further understanding of this regularly prescribed drug will help us&#xD;
      to better understand the complex mechanisms of pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>all 20 minutes up to 180 minutes after starting the experiment</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracetamol/Tropisetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Proband will receive Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropisetron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proband will receive Tropisetron alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 1 g i.v. once</description>
    <arm_group_label>Paracetamol</arm_group_label>
    <arm_group_label>Paracetamol/Tropisetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropisetron</intervention_name>
    <description>Tropisetron 5 mg i.v. once</description>
    <arm_group_label>Paracetamol/Tropisetron</arm_group_label>
    <arm_group_label>Tropisetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers&#xD;
&#xD;
          -  20-35 years of age&#xD;
&#xD;
          -  No known medical disorders&#xD;
&#xD;
          -  BMI 18.5 - 39.9 (kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known drug allergies (paracetamol, tropisetron)&#xD;
&#xD;
          -  Excessive consumption of tobacco (more than 10 cigarettes a day)&#xD;
&#xD;
          -  Excessive consumption of tea or coffee (more than 5 cups a day)&#xD;
&#xD;
          -  Recreational drug addiction&#xD;
&#xD;
          -  Consumption of any medication on the trial days&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Ruppen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paracetamol</keyword>
  <keyword>Tropisetron</keyword>
  <keyword>Central analgesic effect</keyword>
  <keyword>Area of allodynia</keyword>
  <keyword>Secondary hyperalgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tropisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

